502433-34-3

Upstream product

• 502607-40-1 4-{[(2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]methoxy}benzoyl chloride 
• 359586-15-5 benzyl (2-methyl-1H-indol-4-yl)acetate 
• 359586-00-8 2-methylindole-4-acetic acid 
• 359585-96-9 2-methyl-1H-indol-4-yl trifluoromethanesulfonate 
• 35320-67-3 4-hydroxy-2-methyl-1H-indole 
• 386702-75-6 (S)-2-hydroxymethyl-4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine 
• 359586-17-7 1-(4-hydroxybenzoyl)-2-methyl-1H-indol-4-yl acetic acid benzyl ester 
• 359586-16-6 benzyl {1-[4-(acetoxy)benzoyl]-2-methyl-1H-indol-4-yl}acetate 
• 359585-97-0 tert-butyl 2-methyl-4-{[(trifluoromethyl)sulfonyl]oxy}-1H-indole-1-carboxylate 
• 359585-98-1 tert-butyl 2-methyl-4-[(trimethylsilyl)ethynyl]-1H-indole-1-carboxylate 
• 359585-99-2 1-tert-butoxycarbonyl-2-methyl-1H-indol-4-yl acetic acid 

Relevant academic research and scientific papers

INDOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT

Indole derivatives represented by formula (I) ???wherein all symbols represent the same as that in specification), production methods thereof, and DP receptor antagonist comprising them as active ingredients. Since the compounds of formula (I) binds and antagonizes to DP receptor, they are useful for the prevention and/or treatment against allergic diseases, diseases accompanied with itching, secondary diseases generated by behaviors caused by itching, inflammation, chronic obstructive pulmonary disease, ischemic reperfusion disorder, cerebrovascular disorder, pleuritis complicated by rheumatoid arthritis, ulcerative colitis.

Discovery of orally active prostaglandin D2 receptor antagonists

Discovery process of a new PGD2 receptor antagonists 3i is reported. A series of N-(p-alkoxy)benzoyl-2-methylindole-4-acetic acids were synthesized and evaluated for prostaglandin D2 (DP) receptor affinity and antagonist activity. So